During the past decade, Women's Cancer Center conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 10 clinical trials were completed, i.e. on average, 142.9% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 6 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Women's Cancer Center" #1 sponsor was "Gynecologic Oncology Group" with 19 trials, followed by "Pfizer" with 8 trials sponsored, "Alliance Foundation Trials, LLC." with 1 trials sponsored, "Aravive, Inc." with 1 trials sponsored and "AstraZeneca" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Women's Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 19 trials as a collaborator, "GOG Foundation" with 2 trials as a collaborator, "Medivation, Inc." with 2 trials as a collaborator, "Myriad Genetic Laboratories, Inc." with 2 trials as a collaborator and "Austrian Breast & Colorectal Cancer Study Group" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Women's Cancer Center" are "Ovarian Cancer" (11 trials), "Primary Peritoneal Cavity Cancer" (10 trials), "Breast Neoplasms" (3 trials), "Cervical Cancer" (3 trials) and "Endometrial Cancer" (3 trials). Many other conditions were trialed in "Women's Cancer Center" in a lesser frequency.

Most popular intervention types in "Women's Cancer Center" are "Drug" (31 trials), "Procedure" (3 trials), "Biological" (2 trials), "Radiation" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "cisplatin" (7 trials), "paclitaxel" (7 trials), "doxorubicin hydrochloride" (3 trials), "PF-03084014" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Women's Cancer Center" are 26 trials for "Female" genders and 6 trials for "All" genders.

Currently, there are NaN active trials in "Women's Cancer Center". undefined are not yet recruiting, undefined are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Women's Cancer Center, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Women's Cancer Center, 5 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".